MA53644A - Immunothérapie à l'aide de peptides restreints par a*01 et combinaison de peptides pour lutter contre des cancers et méthodes associées - Google Patents

Immunothérapie à l'aide de peptides restreints par a*01 et combinaison de peptides pour lutter contre des cancers et méthodes associées

Info

Publication number
MA53644A
MA53644A MA053644A MA53644A MA53644A MA 53644 A MA53644 A MA 53644A MA 053644 A MA053644 A MA 053644A MA 53644 A MA53644 A MA 53644A MA 53644 A MA53644 A MA 53644A
Authority
MA
Morocco
Prior art keywords
peptides
immunotherapy
combination
related methods
combating cancer
Prior art date
Application number
MA053644A
Other languages
English (en)
Inventor
Jens Fritsche
Daniel Kowalewski
Oliver Schoor
Heiko Schuster
Harpreet Singh
Colette Song
Annika Sonntag
Toni Weinschenk
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68062920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53644(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MA53644A publication Critical patent/MA53644A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA053644A 2018-09-18 2019-09-18 Immunothérapie à l'aide de peptides restreints par a*01 et combinaison de peptides pour lutter contre des cancers et méthodes associées MA53644A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862732863P 2018-09-18 2018-09-18
DE102018122900 2018-09-18

Publications (1)

Publication Number Publication Date
MA53644A true MA53644A (fr) 2021-07-28

Family

ID=68062920

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053644A MA53644A (fr) 2018-09-18 2019-09-18 Immunothérapie à l'aide de peptides restreints par a*01 et combinaison de peptides pour lutter contre des cancers et méthodes associées

Country Status (19)

Country Link
US (10) US10954281B2 (fr)
EP (1) EP3852787A1 (fr)
JP (2) JP7476174B2 (fr)
KR (1) KR20210063320A (fr)
CN (1) CN113164569A (fr)
AU (1) AU2019342860A1 (fr)
BR (1) BR112021003511A2 (fr)
CA (1) CA3108582A1 (fr)
CL (3) CL2021000653A1 (fr)
CO (1) CO2021003404A2 (fr)
CR (1) CR20210141A (fr)
IL (2) IL309715A (fr)
MA (1) MA53644A (fr)
MX (1) MX2021003089A (fr)
PE (1) PE20211643A1 (fr)
PH (1) PH12021550581A1 (fr)
SG (1) SG11202101926TA (fr)
TW (1) TW202024121A (fr)
WO (1) WO2020058360A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201841934A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於治療癌症免疫治療的新穎肽及其肽組合物
CR20210160A (es) 2017-04-10 2021-04-26 Immatics Biotechnologies Gmbh Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508)
WO2021188743A2 (fr) * 2020-03-20 2021-09-23 Neo7Logix, Llc Système informatisé d'augmentation immuno-moléculaire basée sur la précision (pbima), procédé et vaccin thérapeutique
US12525329B2 (en) * 2020-03-20 2026-01-13 Neo7Bioscience, Inc. Precision-based immuno-molecular augmentation (PBIMA) computerized system, method, and therapeutic vaccine
JP7822953B2 (ja) * 2020-04-14 2026-03-03 ウニヴェルシテ ド モントリオール 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用
CN115843747B (zh) * 2022-12-02 2024-08-20 吉林大学 一种Lama3基因点突变的小鼠模型及其构建方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
CA2163032C (fr) 1993-06-03 2001-02-06 John Landon Fragments d'anticorps a des fins therapeutiques
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1294748B1 (fr) 2000-03-27 2010-06-30 Technion Research and Development of Foundation, Ltd. Complexes majeurs d'histocompatibilite monocatenaires de classe 1, constructions les codant et leurs methodes de production
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP2322228B1 (fr) 2000-06-05 2018-01-10 Altor BioScience Corporation Protéines de fusion et conjugués de récepteurs de lymphocytes T et procédés d'utilisation de ceux-ci
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
EP2048159B1 (fr) 2002-11-09 2014-01-01 Immunocore Ltd. Présentation de récepteur de lymphocyte T
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
DE602005020046D1 (de) 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
WO2010037395A2 (fr) 2008-10-01 2010-04-08 Dako Denmark A/S Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2632955A1 (fr) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Anticorps qui se lient à des ligands de récepteurs de lymphocytes t solubles
WO2013057586A1 (fr) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions et procédés de production de récepteurs solubles des lymphocytes t
WO2014071978A1 (fr) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Acides nucléiques codant pour des polypeptides chimériques pour criblage de banque
EP2808392A1 (fr) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamères et utilisation de ces aptamères dans le diagnostic et le traitement du cancer
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
CA3172682A1 (fr) 2015-04-23 2016-10-27 Nantomics, Llc Neo-epitopes de cance
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
GB201609193D0 (en) * 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
US11175289B2 (en) * 2016-11-16 2021-11-16 Lei Han Application of TRPM8 protein, related peptide fragment and their antibodies
JP7722629B2 (ja) 2017-07-04 2025-08-13 キュアバック エスイー 新規核酸分子

Also Published As

Publication number Publication date
US20200087364A1 (en) 2020-03-19
JP7476174B2 (ja) 2024-04-30
CL2021000653A1 (es) 2021-08-20
WO2020058360A1 (fr) 2020-03-26
CL2023000659A1 (es) 2023-08-18
US20220002366A1 (en) 2022-01-06
TW202024121A (zh) 2020-07-01
US20200325199A1 (en) 2020-10-15
US20200325198A1 (en) 2020-10-15
US12195506B2 (en) 2025-01-14
US20200325197A1 (en) 2020-10-15
CO2021003404A2 (es) 2021-04-08
US10954281B2 (en) 2021-03-23
CL2023000658A1 (es) 2023-08-18
CN113164569A (zh) 2021-07-23
JP2022502358A (ja) 2022-01-11
US12060399B2 (en) 2024-08-13
US20220009982A1 (en) 2022-01-13
MX2021003089A (es) 2021-05-12
US20200325196A1 (en) 2020-10-15
US10899814B2 (en) 2021-01-26
US20210238243A1 (en) 2021-08-05
CR20210141A (es) 2021-06-10
SG11202101926TA (en) 2021-04-29
PE20211643A1 (es) 2021-08-24
US10899813B2 (en) 2021-01-26
IL281596A (en) 2021-05-31
PH12021550581A1 (en) 2021-11-29
US20200325195A1 (en) 2020-10-15
US11001617B2 (en) 2021-05-11
AU2019342860A1 (en) 2021-03-04
IL309715A (en) 2024-02-01
US10870685B2 (en) 2020-12-22
US10899812B2 (en) 2021-01-26
KR20210063320A (ko) 2021-06-01
US11142556B2 (en) 2021-10-12
EP3852787A1 (fr) 2021-07-28
BR112021003511A2 (pt) 2021-05-18
US20250092104A1 (en) 2025-03-20
CA3108582A1 (fr) 2020-03-26
JP2024102112A (ja) 2024-07-30

Similar Documents

Publication Publication Date Title
MA53326A (fr) Immunothérapie à l'aide de peptides restreints par b*07 et combinaison de peptides contre des cancers et méthodes associées
EP3589646A4 (fr) Compositions à base de cd19 et méthodes pour l'immunothérapie
EP3609914A4 (fr) Lymphocytes t récepteurs d'antigènes chimériques ciblant le micro-environnement tumoral
EP3565739A4 (fr) Panorama de vues assemblées par l'arrière pour une visualisation de vue arrière
MA53641A (fr) Peptides restreints b*44 destinés à être utilisés en immunothérapie contre des cancers et méthodes associées
MA50542A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre le cancer ovarien épithélial et d'autres cancers
EP3463202C0 (fr) Implant à plaques d'extrémité indépendantes
EP4070290A4 (fr) Génération de représentations souterraines à l'aide d'espace-couche
EP3271401A4 (fr) Conjugués pour le traitement du cancer ciblant les antigènes associés aux tumeurs intracellulaires
EP3781131A4 (fr) Modulation thérapeutique de suppresseurs tumoraux à l'aide d'exosomes
SG11202103134TA (en) Nitroxoline prodrug and use thereof
MA47367A (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
EP3658683A4 (fr) Découverte d'épitopes à médiation par trogocytose
EP3496743A4 (fr) Compositions et méthodes pour le traitement du cancer par déplétion en arginine et à l'aide d'agents d'immuno-oncologie
MA54519A (fr) Immunothérapie à l'aide de peptides restreints par b*08 et combinaison de peptides contre des cancers et méthodes associées
EP4137643C0 (fr) Ensemble d'usure
EP3941512A4 (fr) Traitement de cancers à l'aide des protéines de fusion sephb4-hsa
IL279622A (en) Pharmaceutical formulations of masked antibodies
MA49123A (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre les leucémies et d'autres cancers
AU2018301651A1 (en) A peptide saporin conjugate for the treatment of cancer
MA52614A (fr) Peptides destinés à être utilisés en immunothérapie contre des cancers
EP3773492A4 (fr) Ciblage thérapeutique d'oncogènes à l'aide d'exosomes
EP3922251A4 (fr) Adjuvant d'immunothéraphie anticancéreuse
EP3958972A4 (fr) Médicament thérapeutique pour la dyskinésie
EP3976641A4 (fr) Constructions d'immunothérapie ciblant des antigènes kras